white → brown1
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
MT-45
MT-45 is a synthetic opioid1 and piperazine derivative that is structurally distinct from most other opioids.1 It was developed by Dainippon Pharmaceutical in the 1970s.2 Its effects combine opioid and dissociative features, with users generally reporting limited euphoria compared with other opioids. Persistent hearing loss has been associated with its use2, and hair loss has also been reported1, raising concerns particularly about regular use or high doses.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold30 mg
Light30-45 mg
Moderate45-60 mg
Strong60+ mg
Duration
Onset30-45 minutes
After Effects2-3 hours
Total4-6 hours
Subjective Effects
Subjective Effects not written up yet
Pharmacology
Pharmacodynamics
MT-45 acts as a μ-opioid receptor agonist3, with almost all of its opioid activity attributable to the (S) enantiomer. The (R) enantiomer has weaker μ-opioid agonist activity, while the (S) enantiomer has higher affinity for κ- and δ-opioid receptors. The (R) enantiomer may also antagonize sigma-1 and sigma-2 receptors, based on findings that sigma agonists reverse some of its actions in mice.
Pharmacokinetics
MT-45 metabolism produces a major metabolite that blocks NMDA receptors.
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance not written up yet
Harm Potential
Addiction & Dependence
Psychological
MT-45 can be habit-forming, and addiction is possible, although users generally report disliking it and few reportedly continue prolonged use. A desire to redose can occur before effects begin and during the comedown.
Toxicity
Recreational MT-45 use has been associated with hair depigmentation, alopecia, dermatitis, and Mees lines in the nails.
Recreational MT-45 use has been associated with cataracts.9
Fatal and nonfatal MT-45 overdoses can cause drowsiness, unconsciousness, and coma.
Fatal and nonfatal MT-45 overdoses can cause respiratory depression, hypoxia, and cyanosis.
Tachycardia can occur in fatal and nonfatal MT-45 overdoses.
History & Culture
MT-45 was developed in the 1970s by the Japanese company Dainippon Pharmaceutical Co.6 during investigations of compounds structurally related to perathiepine and lefetamine.6 It later served as a lead compound for the development of a large family of…
Legality
By Country
Illegal3
United StatesIllegalMT-45 is listed by exact name in Schedule I of 21 C.F.R. § 1308.11(b)(71), under DEA controlled-substance code 9560, and has been permanently scheduled since January 12, 2018. Under federal law, unauthorized possession, manufacture, distribution, dispensing, import, and export are prohibited, as is possession with intent to manufacture, distribute, or dispense. Research and instructional activities involving MT-45 are also federally controlled.
Czech RepublicIllegalNařízení vlády č. 463/2013 Sb., o seznamech návykových látek, příloha č. 3; zákon č. 167/1998 Sb., o návykových látkách, § 415161718
MT-45 is listed by exact name and as 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine in Annex No. 3, List No. 3 of narcotic substances, of Government Regulation No. 463/2013 Coll. Substances and preparations containing List No. 3 narcotics may be used only for limited research and scientific purposes and very limited therapeutic purposes specified in a handling permit. Section 4 of Act No. 167/1998 Coll. requires a permit to handle addictive substances and preparations unless the Act provides otherwise.
United KingdomIllegalMisuse of Drugs Act 1971, Schedule 2 Part I; Misuse of Drugs Regulations 2001, Schedule 1; Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015, Schedule 1 Part 1; Misuse of Drugs Regulations (Northern Ireland) 2002, Schedule 1; Misuse of Drugs (Designation) Order (Northern Ireland) 2001, Schedule 1 Part 119202122232425262728
MT-45 is named in Schedule 2 Part I of the Misuse of Drugs Act 1971 as a Class A drug and is placed under the corresponding Schedule 1 and designation controls in Great Britain and Northern Ireland. The Act prohibits possession, possession with intent to supply, production, supply, offering to supply, import and export unless authorised; domestic possession, production and supply require a Home Office licence in Great Britain and a Northern Ireland Department of Health licence in Northern Ireland. The Home Office administers import and export licensing throughout the United Kingdom. The Class A classification took effect throughout the United Kingdom on 11 March 2015; initial Schedule 1 and designation placement took effect on that date in England, Wales and Scotland and on 13 May 2015 in Northern Ireland.
References
Citations
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the MT-45 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
